Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults males or females between 18-39 years of age at the day of screening.~* Willing and able to comply with scheduled visits, laboratory test, complete diaries and other study procedures.~* Body Mass Index 18 to 40 Kg/m2 at screening.~* COVID19 negative PCR test and negative serum IgG binding antibody response to the SARS-CoV-2 S glycoprotein at screening or prior the first vaccination.~* Willing to avoid all other vaccines within 4 weeks before and after each injection. Seasonal influenza vaccination is allowed if it is received at least 14 days before or after the vaccination.~* Women of childbearing potential must have a negative pregnancy test in urine before the inclusion of the study and prior to each vaccination.~* If female of childbearing potential, willing to use highly effective contraceptive methods or have practiced sexual abstinence from the screening visit until 8 weeks after the last injection.~* If male and not sterilized, willing to avoid impregnating female partners from screening until 18 weeks after last injection.~* Willing and able to provide written informed consent prior the initiation of any study procedures.~Exclusion Criteria:~* Pregnant or lactating or intending to become pregnant or plans to breastfeed during the study.~* Positive pregnancy test at screening or prior to each vaccination.~* Any medical disease (acute, subacute, intermittent or chronic) or condition that in the opinion of the investigator compromise the volunteer's safety, preclude vaccination or compromise interpretation of the results.~* History of serious psychiatric condition likely to affect participation in the study (e-g- ongoing severe depression, history of admission to an in-patient psychiatric facility, recent suicidal ideation, history of suicide attempt, bipolar disorder, personality disorder, alcohol and drug dependency, severe eating disorder, psychosis, use of mood stabilisers or antipsychotic medication).~* History of respiratory disease (e.g., chronic obstructive pulmonary disease (COPD) and asthma) requiring any daily medications currently or any treatment of respiratory disease exacerbations (e.g., asthma exacerbation) in the last 5 years.~* History of significant cardiovascular disease including hypertension (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.~* History of neurological or neurodevelopmental conditions (e.g., migraines, epilepsy, stroke, seizures in the last 3 years, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis).~* Ongoing malignancy or recent diagnosis of malignancy in the last five years excluding basal cell and squamous cell carcinoma of the skin, which are allowed.~* Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent severe infections.~* Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital).~* Acute illness within 72 hours prior each vaccination that in the opinion of the investigator may interfere the evaluation of safety parameters.~* Usage of any investigational drug ≤ 90 days prior to study entry or plan to participate in another research involving an investigational product (drug/biologic/device) within 12 months after the first study vaccination.~* History of hypersensitivity or severe allergic reaction including anaphylaxis, generalized urticarial, angioedema and other significant reactions related to food, drugs, vaccines or pharmaceutical agents.~* History of allergic disease or reactions likely to be exacerbated by any component of the COVID-19 vaccine HIPRA.~* Use of any immunosuppressant, glucocorticoids, or other immune-modifying drugs within 2 months prior to first study vaccination; or anticipation of the need for immunosuppressive treatment within 6 months after last vaccination.~* Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination.~* Known disturbance of coagulation (iatrogenic or congenital) or blood dyscrasias.~* Known bleeding disorder (e-g- factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture.~* Chronic liver disease.~* Positive test for HIV types 1 or 2 infection, hepatitis B surface antigen (HBsAg), or hepatitis C virus antibodies (HCV Abs) at screening.~* Suspected or known current alcohol abuse or any other substances abuse (except tobacco).~* History of COVID-19 infection.~* Receipt of medications intended to prevent COVID-19.~* Ever received an experimental vaccine against COVID-19.~* Close contact of anyone known to have SARS-CoV-2 infection within 15 days prior to screening visit.~* Being directly involved in the conduct of the study.~* Any condition and/or laboratory finding that at the investigator consideration would interfere with the study or put at risk the participant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- COVID-19 vaccine HIPRA (Type: EXPERIMENTAL): Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart.
- Commercial COVID-19 vaccine (Type: ACTIVE_COMPARATOR): Subjects will receive 2 injections of commercial COVID-19 vaccine administered 21 days apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete